Press release
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Revenue, Insights, Overview, Outlook, Analysis | Valuates Reports
Commercializing Biomarkers in Therapeutic and Diagnostic Applications MarketThe global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at US$ 22500 million in 2022 and is anticipated to reach US$ 29810 million by 2029, witnessing a CAGR of 4.8% during the forecast period 2023-2029.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-5U12923/Global_Commercializing_Biomarkers_in_Therapeutic_and_Diagnostic_Applications_Market_Research_Report_2023
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
A biomarker is, according to the US National Institutes of Health, "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention."
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
By Type
• Consumables
• Services
• Software
By Application
• Oncology
• Cardiology
• Neurology
• Other
Key Players
Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia, ALMAC, Arrayit, Biocartic, BG Medicine, KEGG EXPRESSION Database, Thermo Fisher, BGI
View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-5U12923/global-commercializing-biomarkers-in-therapeutic-and-diagnostic-applications
Similar Reports:
1. https://reports.valuates.com/market-reports/QYRE-Auto-10M7912/global-parp-inhibitor-biomarkers-testing-product
2. https://reports.valuates.com/market-reports/QYRE-Auto-36K9928/global-cardiac-marker-testing-kits
3. https://reports.valuates.com/market-reports/QYRE-Auto-3E3424/global-tumor-biomarker-test
Phone:
U.S. (TOLL FREE) : +1 (315) 215-3225
India: +91 8040957137
Email Id:
Please reach us at sales@valuates.com
Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Revenue, Insights, Overview, Outlook, Analysis | Valuates Reports here
News-ID: 3210047 • Views: …
More Releases from Valuates Reports
Software-Defined Everything (SDE) Market Size, Trends & Forecasts | Valuates Rep …
Software-Defined Everything (SDE) Market
Software-defined everything (SDE) is an umbrella term for a number of technologies that are helping redefine IT. Currently, this group of technologies encompasses software-defined networking (SDN), software-defined storage (SDS), and software-defined data centers (SDDC). Each approach aims to abstract the operating environment from physical infrastructure, while automating the processes that manage the infrastructure. By freeing businesses from proprietary hardware and simplifying the provisioning and management of IT…
AI Server Market Size, Trends & Forecasts | Valuates Reports
AI Server Market Size
The global AI Server market is projected to grow from US$ 31720 million in 2024 to US$ 78810 million by 2030, at a Compound Annual Growth Rate (CAGR) of 16.4% during the forecast period.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-24S15068/Global_AI_Server_Market_Research_Report_2023?utm_source=openpr&utm_medium=referral&utm_campaign=openpr_referral
Major Trends
The global AI server market is driven by several key factors, including the rising adoption of artificial intelligence across various industries, advancements in AI technology, and the increasing need for…
Precision Air Conditioner Market Size, Trends & Forecasts | Valuates Reports
Precision Air Conditioner Market Size
The global Precision Air Conditioner revenue was US$ 4926.8 million in 2022 and is forecast to a readjusted size of US$ 7815.6 million by 2029 with a CAGR of 6.8% during the forecast period (2023-2029).
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-38A15722/Global_and_India_Precision_Air_Conditioner_Market_Report_Forecast_2023_2029?utm_source=openpr&utm_medium=referral&utm_campaign=openpr_referral
The key precision air conditioning manufacturers are Vertiv, Stulz, Daikin etc. Top 3 companies occupied about 30% market share. China is the largest market, with a share about 35%,…
Non-Segregated Phase Bus Duct Market Set to Surge - Key Insights You Must Know
Non-Segregated Phase Bus Duct Market
Non-segregated phase bus is an assembly of bus conductors with associated connections, joints, and insulating supports confined within a metal enclosure without interphase barriers.
The global Non-Segregated Phase Bus Duct market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-21G10197/Global_Non_Segregated_Phase_Bus_Duct_Market_Insights_Forecast_to_2028?utm_source=openpr&utm_medium=referral&utm_campaign=openpr_referral
North American market for Non-Segregated Phase Bus Duct…
More Releases for Commercializing
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market 202 …
According to Market Study Report, Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market provides a comprehensive analysis of the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample PDF (including full TOC, Tables and Figures) of Commercializing Biomarkers…
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Mar …
This new report by Eon Market Research, titled “Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry at a global as well as regional and country level. Key facts analyzed in this report include the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size by players, regions, product types and end…
Commercializing Biomarkers Market Research Report 2018 to 2026
In this report, the key data information like sales, revenue are market share, growth rate (CAGR) are the most important contents. We focus these key data by top manufacturers, regions, product type and applications. History data from 2014 to 2018, and projected out to the year 2026. The forecast data is based on the history data in the past several years.
This report includes the estimation of market size for value…
Asthma - Identifying and Commercializing First-in-Class Innovation | Latest Mark …
Researchmoz added Most up-to-date research on "Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough…
Frontier Pharma: Pancreatic Cancer - Identifying And Commercializing First-In-Cl …
Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.
A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms…
Frontier Pharma: Psoriasis - Identifying And Commercializing First-In-Class Inno …
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484…
